Loading…
Loading…
would you consider revisiting that endemic rate as we get towards your end? Would you potentially revisit it for a fifth time
how are you thinking about the timing of recovery on bio-processing equipment given those dynamics
What types of products are you seeing the most weakness in in that research market
did you see orders grow high-single digits again this quarter sequentially or was order growth slightly less
how should we think about the pace of recovery throughout the year on Bioprocessing
Can you walk us through are you expecting Danaher to be impacted this - by this at all
could you break down for us what percent of that $500 million update was related to ENG versus the CRO
Can you walk us through your broad pricing assumptions, expectations for this year? How much do you really think you will be able to mitigate
can you walk us through what have you seen since the new administration turnover in terms of customers' behavior
can you walk us through some of the drivers of that beat? Did you guys see any budget flush trends in the quarter